Tumor Lysis Syndrome: New Challenges and Recent Advances

Advances in Chronic Kidney Disease

Volumn 21, Issue 1, 2014, Pages 18-26

  Wilson, F Perry ^a   Berns, Jeffrey S ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute kidney failure; Acute kidney injury; Oncologic emergencies; Rasburicase; Tumor lysis syndrome

Indexed keywords

ALLOPURINOL; CALCIUM; DIURETIC AGENT; FEBUXOSTAT; RECOMBINANT URATE OXIDASE;

ACUTE DISEASE; ALKALINIZATION; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PREVENTION; CANCER THERAPY; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR LYSIS SYNDROME; URIC ACID NEPHROPATHY;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY INJURY; ONCOLOGIC EMERGENCIES; RASBURICASE; TUMOR LYSIS SYNDROME;

ACUTE KIDNEY INJURY; ALLOPURINOL; BICARBONATES; BUFFERS; CALCIUM; DIURETICS; ENZYME INHIBITORS; FLUID THERAPY; HUMANS; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOCALCEMIA; RENAL DIALYSIS; THIAZOLES; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 84890574505     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2013.07.001     Document Type: Review

References (95)

1. Jasek A.M., Day H.J. Acute spontaneous tumor lysis syndrome. Am J Hematol 1994, 47(2):129-131.
2. Flombaum C.D. Metabolic emergencies in the cancer patient. Semin Oncol 2000, 27(3):322-334.
3. Cairo M.S., Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004, 127(1):3-11.
4. Wossmann W., Schrappe M., Meyer U., Zimmerman M., Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003, 82(3):160-165.
5. Howard S.C., Jones D.P., Pui C.H. The tumor lysis syndrome. N Engl J Med 2011, 364(19):1844-1854.
6. Lewis M.A., Hendrickson A.W., Moynihan T.J. Oncologic emergencies: pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin 2011, 61(5):287-314.
7. Abu-Alfa A.K., Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis 2010, 55(5 suppl 3):S1-S13. quiz S14-19.
8. Noh G.Y., Choe D.H., Kim C.H., Lee J.C. Fatal tumor lysis syndrome during radiotherapy for non-small-cell lung cancer. J Clin Oncol 2008, 26(36):6005-6006.
9. Fleming D.R., Henslee-Downey P.J., Coffey C.W. Radiation induced acute tumor lysis syndrome in the bone marrow transplant setting. Bone Marrow Transplant 1991, 8(3):235-236.
10. McDonnell C., Barlow R., Campisi P., Grant R., Malkin D. Fatal peri-operative acute tumour lysis syndrome precipitated by dexamethasone. Anaesthesia 2008, 63(6):652-655.
11. Fuente N., Mane J.M., Barcelo R., Munoz A., Perez-Hoyos T., Lopez-Vivanco G. Tumor lysis syndrome in a multiple myeloma treated with thalidomide. Ann Oncol 2004, 15(3):537.
12. Lee C.C., Wu Y.H., Chung S.H., Chen W.J. Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma. Oncologist 2006, 11(1):87-88. author reply 89.
13. Furtado M., Rule S. Bortezomib-associated tumor lysis syndrome in multiple myeloma. Leuk Lymphoma 2008, 49(12):2380-2382.
14. Lipstein M., O'Connor O., Montanari F., Paoluzzi L., Bongero D., Bhagat G. Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma. Clin Lymphoma Myeloma 2010, 10(5):E43-E46.
15. Francescone S.A., Murphy B., Fallon J.T., Hammond K., Pinney S. Tumor lysis syndrome occurring after the administration of rituximab for posttransplant lymphoproliferative disorder. Transplant Proc 2009, 41(5):1946-1948.
16. Sezer O., Vesole D.H., Singhal S., et al. Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma 2006, 7(3):233-235.
17. Riccio B., Mato A., Olson E.M., Berns J.S., Luger S. Spontaneous tumor lysis syndrome in acute myeloid leukemia-two cases and a review of the literature. Cancer Biol Ther 2006, 5(12):1614-1617.
18. Akoz A.G., Yildirim N., Engin H., et al. An unusual case of spontaneous acute tumor lysis syndrome associated with acute lymphoblastic leukemia: a case report and review of the literature. Acta Oncol 2007, 46(8):1190-1192.
19. Agnani S., Gupta R., Atray N.K., Vachharajani T.J. Marked hyperuricemia with acute renal failure: need to consider occult malignancy and spontaneous tumour lysis syndrome. Int J Clin Pract 2006, 60(3):364-366.
20. Chao C.T., Chiang C.K. Rasburicase for huge hepatocellular carcinoma with tumor lysis syndrome: case report. Med Princ Pract 2012, 21(5):498-500.
21. Kaplan M.A., Kucukoner M., Alpagat G., Isikdogan A. Tumor lysis syndrome during radiotherapy for prostate cancer with bone and bone marrow metastases without visceral metastasis. Ann Saudi Med 2012, 32(3):306-308.
22. Baeksgaard L., Sorensen J.B. Acute tumor lysis syndrome in solid tumors-a case report and review of the literature. Cancer Chemother Pharmacol 2003, 51(3):187-192.
23. Liberopoulos E.N., Kei A.A., Elisaf M.S. Lysis syndrome during therapy of visceral leishmaniasis. Infection 2012, 40(2):121-123.
24. Seidemann K., Meyer U., Jansen P., et al. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin's lymphoma and B-ALL. Observations from the BFM-trials. Klin Padiatr 1998, 210(4):279-284.
25. Montesinos P., Lorenzo I., Martin G., et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologia 2008, 93(1):67-74.
26. Mato A.R., Riccio B.E., Qin L., et al. A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk Lymphoma 2006, 47(5):877-883.
27. Truong T.H., Beyene J., Hitzler J., et al. Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome. Cancer 2007, 110(8):1832-1839.
28. Annemans L., Moeremans K., Lamotte M., et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma 2003, 44(1):77-83.
29. Darmon M., Guichard I., Vincent F., Schlemmer B., Azoulay E. Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma 2010, 51(2):221-227.
30. Tsokos G.C., Balow J.E., Spiegel R.J., Magrath I.T. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore) 1981, 60(3):218-229.
31. Canduri F., dos Santos D.M., Silva R.G., et al. Structures of human purine nucleoside phosphorylase complexed with inosine and ddI. Biochem Biophys Res Commun 2004, 313(4):907-914.
32. Shimada M., Johnson R.J., May W.S., et al. A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transplant 2009, 24(10):2960-2964.
33. Conger J.D., Falk S.A. Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 1977, 59(5):786-793.
34. Kang D.H., Park S.K., Lee I.K., Johnson R.J. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005, 16(12):3553-3562.
35. Cirillo P., Gersch M.S., Mu W., et al. Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells. J Am Soc Nephrol 2009, 20(3):545-553.
36. Han H.J., Lim M.J., Lee Y.J., Lee J.H., Yang I.S., Taub M. Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-kappaB. Am J Physiol Renal Physiol 2007, 292(1):F373-F381.
37. Cividalli G., Nathan D.G. Sodium and potassium concentration and transmembrane fluxes in leukocytes. Blood 1974, 43(6):861-869.
38. Lichtman M.A., Weed R.I. The monovalent cation content and adenosine triphosphatase activity of human normal and leukemic granulocytes and lymphocytes: relationship to cell volume and morphologic age. Blood 1969, 34(5):645-660.
39. Cohen L.F., Balow J.E., Magrath I.T., Poplack D.G., Ziegler J.L. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med 1980, 68(4):486-491.
40. Hsu H.H., Lin J.Y., Hsu S.C., Chan Y.L., Huang C.C. Neglected cause of renal failure in cancer patients: spontaneous tumor lysis syndrome inducing acute uric acid nephropathy. Dial Transplant 2004, 33(6):316-325.
41. Filippatos T.D., Milionis H.J., Elisaf M.S. Alterations in electrolyte equilibrium in patients with acute leukemia. Eur J Haematol 2005, 75(6):449-460.
42. Martin A., Acierno M.J. Continuous renal replacement therapy in the treatment of acute kidney injury and electrolyte disturbances associated with acute tumor lysis syndrome. J Vet Intern Med 2010, 24(4):986-989.
43. Boles J.M., Dutel J.L., Briere J., Mialon P., Robasckiewicz M., Garre M. Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer 1984, 53(11):2425-2429.
44. Cadman E.C., Lunberg W.B., Bertino J.R. Hyperphosphatermia and hypocalcemia accompanying rapid cell lysis in a patient with Burkitt's lymphoma and Burkitt cell leukemia. Am J Med 1977, 62(2):283-290.
45. Dunlay R.W., Camp M.A., Allon M., Fanti P., Malluche H.H., Llach F. Calcitriol in prolonged hypocalcemia due to the tumor lysis syndrome. Ann Intern Med 1989, 110(2):162-164.
46. Moe S.M. Disorders involving calcium, phosphorus, and magnesium. Prim Care 2008, 35(2):215-237. v-vi.
47. Will A., Tholouli E. The clinical management of tumour lysis syndrome in haematological malignancies. Br J Haematol 2011, 154(1):3-13.
48. Tosi P., Barosi G., Lazzaro C., et al. Consensus conference on the management of tumor lysis syndrome. Haematologica 2008, 93(12):1877-1885.
49. Davidson M.B., Thakkar S., Hix J.K., Bhandarkar N.D., Wong A., Schreiber M.J. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004, 116(8):546-554.
50. Rampello E., Fricia T., Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol 2006, 3(8):438-447.
51. Jones D.P., Mahmoud H., Chesney R.W. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 1995, 9(2):206-212.
52. Bellinghieri G., Santoro D., Savica V. Pharmacological treatment of acute and chronic hyperuricemia in kidney diseased patients. Contrib Nephrol 2005, 147:149-160.
53. Band P.R., Silverberg D.S., Henderson J.F., et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 1970, 283(7):354-357.
54. LaRosa C., McMullen L., Bakdash S., et al. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol 2007, 22(1):132-135.
55. Cairo M.S., Coiffier B., Reiter A., Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010, 149(4):578-586. TLS Expert Panel.
56. Arellano F., Sacristan J.A. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993, 27(3):337-343.
57. Vazquez-Mellado J., Morales E.M., Pacheco-Tena C., Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001, 60(10):981-983.
58. Hung S.I., Chung W.H., Liou L.B., et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005, 102(11):4134-4139.
59. Young J.L., Boswell R.B., Nies A.S. Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise. Arch Intern Med 1974, 134(3):553-558.
60. McKendrick M.W., Geddes A.M. Allopurinol hypersensitivity. Br Med J 1979, 1(6169):988.
61. Gearry R.B., Day A.S., Barclay M.L., Leong R.W., Sparrow M.P. Azathioprine and allopurinol: a two-edged interaction. J Gastroenterol Hepatol 2010, 25(4):653-655.
62. Hoshide S., Takahashi Y., Ishikawa T., et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 2004, 23(8-9):1117-1118.
63. Burns C.M., Wortmann R.L. Gout therapeutics: new drugs for an old disease. Lancet 2011, 377(9760):165-177.
64. Schumacher H.R., Becker M.A., Lloyd E., MacDonald P.A., Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology 2009, 48(2):188-194.
65. Cortes J., Moore J.O., Maziarz R.T., et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter Phase III study. JClin Oncol 2010, 28(27):4207-4213.
66. Browning L.A., Kruse J.A. Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother 2005, 39(11):1932-1935.
67. Malaguarnera M., Vacante M., Russo C., Dipasquale G., Gargante M.P., Motta M. A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. Expert Opin Pharmacother 2009, 10(5):737-742.
68. Kikuchi A., Kigasawa H., Tsurusawa M., et al. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. Int J Hematol 2009, 90(4):492-500.
69. Ishizawa K., Ogura M., Hamaguchi M., et al. Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study. Cancer Sci 2009, 100(2):357-362.
70. Goldman S.C., Holcenberg J.S., Finklestein J.Z., et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001, 97(10):2998-3003.
71. Vadhan-Raj S., Fayad L.E., Fanale M.A., et al. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 2012, 23(6):1640-1645.
72. Lopez-Olivo M.A., Pratt G., Palla S.L., Salahudeen A. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. Am J Kidney Dis 2013, Accessed August 9, 2013. http://dx.doi.org:10.1053/j.ajkd.2013.02.378.
73. Giraldez M., Puto K. A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. Eur J Haematol 2010, 85(2):177-179.
74. Hooman N., Otukesh H. Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases. Iran J Kidney Dis 2011, 5(2):130-132.
75. Hutcherson D.A., Gammon D.C., Bhatt M.S., Faneuf M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy 2006, 26(2):242-247.
76. Knoebel R.W., Lo M., Crank C.W. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. J Oncol Pharm Pract 2011, 17(3):147-154.
77. Lee A.C.W., Li C.H., So K.T., Chan R. Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003, 37(11):1614-1617.
78. Liu C.Y., Sims-McCallum R.P., Schiffer C.A. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res 2005, 29(4):463-465.
79. McDonnell A.M., Lenz K.L., Frei-Lahr D.A., Hayslip J., Hall P.D. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 2006, 26(6):806-812.
80. Reeves D.J., Bestul D.J. Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy 2008, 28(6):685-690.
81. Sestigiani E., Mandreoli M., Guardigli M., et al. Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chronic kidney disease. Nephron Clin Pract 2008, 108(4):c265-c271.
82. Trifilio S., Gordon L., Singhal S., et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 2006, 37(11):997-1001.
83. Trifilio S.M., Pi J., Zook J., et al. Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Bone Marrow Transplant 2011, 46(6):800-805.
84. Vines A.N., Shanholtz C.B., Thompson J.L. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. Ann Pharmacother 2010, 44(10):1529-1537.
85. Hummel M., Reiter S., Adam K., Hehlmann R., Buchheidt D. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur J Haematol 2008, 80(4):331-336.
86. Cheuk D.K., Chiang A.K., Chan G.C., Ha S.Y. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer. Cochrane Database Syst Rev 2010, 6:CD006945.
87. Agha-Razii M., Amyot S.L., Pichette V., Cardinal J., Ouimet D., Leblanc M. Continuous veno-venous hemodiafiltration for the treatment of spontaneous tumor lysis syndrome complicated by acute renal failure and severe hyperuricemia. Clin Nephrol 2000, 54(1):59-63.
88. Sakarcan A., Quigley R. Hyperphosphatemia in tumor lysis syndrome: the role of hemodialysis and continuous veno-venous hemofiltration. Pediatr Nephrol 1994, 8(3):351-353.
89. Pichette V., Leblanc M., Bonnardeaux A., Ouimet D., Geadah D., Cardinal J. High dialysate flow rate continuous arteriovenous hemodialysis: a new approach for the treatment of acute renal failure and tumor lysis syndrome. Am J Kidney Dis 1994, 23(4):591-596.
90. Heney D., Essex-Cater A., Brocklebank J.T., Bailey C.C., Lewis I.J. Continuous arteriovenous haemofiltration in the treatment of tumour lysis syndrome. Pediatr Nephrol 1990, 4(3):245-247.
91. Saccente S.L., Kohaut E.C., Berkow R.L. Prevention of tumor lysis syndrome using continuous veno-venous hemofiltration. Pediatr Nephrol 1995, 9(5):569-573.
92. Choi K.A., Lee J.E., Kim Y.-G., et al. Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. Ann Hematol 2009, 88(7):639-645.
93. Hande K.R., Garrow G.C. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993, 94(2):133-139.
94. Cheson B.D., Frame J.N., Vena D., Quashu N., Sorensen J.M. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 1998, 16(7):2313-2320.
95. Al-Kali A., Farooq S., Tfayli A. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia. J Clin Pharm Ther 2009, 34(5):607-610.